MSD is proud to support the 2018 World Cancer Congress (WCC) in Kuala Lumpur. During this year’s congress, we will be hosting a series of sessions including a moderated expert panel on the role of public-private partnerships to increase access to innovation and immunotherapy, and a full programme for top executives of UICC member organizations with networking and workshopping opportunities as part of the CEO programme.
Sponsored session: Innovative Access Solutions for Immunotherapy Through Public-Private Partnerships
Tuesday 2nd October 2018 - 14:20 – 15:20 – Room 302-303
Unprecedented medical advancements have contributed to great progress in cancer care. Innovative treatment strategies, such as immunotherapy, hold promise to improve outcomes for patients across multiple types of cancer. However, barriers to accessing this innovation remain. This interactive session will bring together patients, health care providers, industry and policy makers to consider the role of public-private partnerships in addressing these challenges.
Building on its tremendous success at the 2016 World Cancer Congress, MSD is proud to sponsor UICC's flagship programme tailored for CEOs of UICC membership. At this year’s Congress, executives will work with a culturally diverse group of peers, and leave the event armed with practical solutions to help them address unique business challenges. This year’s programme includes three interactive lunch workshops, a private networking reception and a CEO Award, which will be presented at the General Assembly. More information is available on the CEO programme page.
Sponsored activities: Driving Global Policy and Inspiring Change for Patients
Pfizer partners with the metastatic breast cancer (mBC) community to support initiatives and organisations that help people with mBC. As part of the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge (SPARC mBC Challenge) initiative, launched in 2015, we have partnered with the Union for International Cancer Control (UICC) to award more than $1.3 million in funding to organizations to support projects that address the specific needs of mBC patients globally.
At this year’s World Cancer Congress, Pfizer will present the latest in policy research through interactive workshops, presentations and activities to encourage the mBC global community to center their focus on patients. Pfizer will have two symposiums, “Initiatives to Support the Patient Journey” and “Patient Driven Data to Drive Change” which will focus on mBC policy gaps, patient data and improving the patient journey. We will also support the SPARC Metastatic Breast Cancer Challenge Master Course Workshop, “Addressing gaps in information, patient support and policy for mBC patients."
Addressing Metastatic Breast Cancer Unmet Needs Through Patient-Focused Policies
Living with metastatic breast cancer remains an ongoing battle for both patients and their caregivers, and resources outside of medicine are vital for improving quality of life. This year at WCC, Pfizer will present the latest in policy research through interactive workshops, presentations and activities to encourage the mBC global community to center their focus on patients.
Leading the Global Charge
Pfizer partners with the mBC community to support initiatives and organizations that help people with mBC. As part of the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge (SPARC mBC Challenge) initiative, launched in 2015, Pfizer has partnered with the Union for International Cancer Control (UICC) to award more than $1.3 million in funding to organizations to support projects that address the specific needs of mBC patients globally.
Pfizer will support the SPARC Metastatic Breast Cancer Challenge Master Course Workshop and will participate in multiple SPARC presentations and program activities.
Pfizer will also be discussing early breast cancer detection and genetic testing policies in the following presentations:
- “Barriers and opportunities in genetic testing for BRCA gene mutations in Europe: a strategic policy response to support women and families at risk of breast cancer” – focuses on the importance of ensuring pathways and policies are in place to integrate the patient experience into comprehensive care pathways and national cancer control plans.
- “Supporting breast cancer early detection and diagnosis: A global metastatic breast cancer policy analysis and promising practice from Brazil” – centers on breast cancer/mBC policy development in 16 countries and identifying opportunities for improvement.
Long after the Congress concludes, Pfizer continues to work with the broader cancer community to support people with breast cancer, so they can live their best lives despite their disease.
Sponsored session: What is the real value of Personalised Healthcare (PHC) in cancer?
Wednesday, 3rd October 2018 - 09:00 - 10:30 - Room 302-303
Advancing towards personalised healthcare
Scientists have begun to understand, target, and diagnose illnesses on a molecular level. Cancer, for instance, is not one disease. We are now aware that there are 250 to 300 types and subtypes of cancer. Doctors can identify the drivers of the disease and therefore better predict how well a patient is going to respond to a treatment.
With the help of diagnostic tools, specific genetic defects or other malfunctions can be detected and treated.
In an era of digital technology, we will be able to increasingly tailor medical treatment to the needs of individuals and small groups of patients. Far more information will be captured, stored and analysed to learn how diseases manifest themselves and how patients experience them day-to-day. Combined with a deeper understanding of molecular science and new methods for diagnostics, this will bring disruptive change to how we research, develop, approve and pay for medicines, as well as how patients and their physicians make decisions about whether, when and how to treat.
Who does PHC Benefit?
- Increased confidence in treatment decisions and improved outcomes for patients
- Improved quality of life and lifetime gained
- Fewer unnecessary treatments and associated costs through smarter decisions on whether, when and how to treat
- More efficient use of funds in the healthcare system
- Higher cure rates
How Do we Get There?
Enabling healthcare systems around the world to build their capacity for PHC will require multi-sectoral collaboration and the knowledge and expertise of all stakeholders.
Join us for the Roche-sponsored session: ‘What is the real value of Personalised Healthcare?’ to explore the value that stakeholders assign to personalised healthcare and discuss how we can collaborate to move PHC forward.
New cancer care model in India
The Tata Trusts in partnership with the Government of India, are rolling out a national step-down distributed cancer centre model, commencing initially in north-east India. In contrast to the current situation where one hospital handles a cancer patient’s journey end-to-end, the model proposes smaller centres close to patients’ home and interlinked with the apex centres, handle diagnosis and care delivery, thereby providing high quality cancer care closer to home. The vision is to create patient-centric cancer centres to deliver standardised and affordable care close to patients’ homes. The programme has six key factors (Infrastructure development / Awareness, prevention, and early detection / Community and hospital palliative care / Integration of clinical guidelines and training / Human resource development / Technology to link centres)
The network will have three levels:
Level 1: comprehensive cancer centres (around 200 beds) providing services ranging from diagnostics to complex therapies and research
Level 2: cancer centres (around 100 beds) located near existing government medical colleges offering common diagnostic and treatment services with complex care being delivered at level 1
Level 3: stand-alone day care cancer units near district hospitals offering diagnostics, chemotherapy, and radiotherapy
Awareness, prevention, and early detection
Health communication, prevention, and screening programmes for early detection thereby shifting the patient profile from late to early stage and improving survival rates.
Community and hospital palliative care given that today more than 60 percent cancers are presented at a late stage
Integration of clinical guidelines and training
Through the National Cancer Grid, a coalition of more than 130 cancer centres in India.
Human resource development
Up-skilling and para-skilling the health-care workforce. Developed by the National Cancer Grid as short term fellowships and certificate courses which will be accredited through state health universities.
Technology to link centres
Implementation of a Digital Nerve Centre to ensure seamless flow of patient information across centres. All the centres will be linked through tele-radiology, tele-pathology, and virtual tumour boards.
American Cancer Society
Sponsored activities: The American Cancer Society is proud to support the 2018 World Cancer Congress (WCC) in Kuala Lumpur
During this year’s congress, ACS will be hosting sessions related to Mission: HPV Cancer Free, a global public health campaign to eliminate vaccine-preventable HPV cancers, starting with cervical cancer. The campaign, which kicked off in the US in 2018, aims to increase vaccination rates among boys and girls to 80% and help to prevent 6 types of cancer associated with HPV. ACS will also roll-out other priority initiatives focused on elimination of combustible tobacco use, lung cancer screening, obesity and cancer, liver cancer, and viral hepatitis.
The American Cancer Society recognizes the power of multi-organizational partnerships in contributing to the recognition of cancer as a global health issue and providing increased prevention, access to care and new treatment options. We will host sessions related to how these collaborations can help to mobilize resources, provide evidence-based messaging for the global stage, as well as highlighting recent successful initiatives within the global cancer treatment space.
2018 Congress Gold Sponsor
Sponsored event: Three Category Winners Announced in C3 Prize Innovation Challenge
Wednesday 3rd October – 15:20 – 16:50 – Conference Hall 3
WCC Attendees Can Watch Live and Vote for Their Favorite Idea on October 3
Astellas is excited to announce the three 2018 Astellas Oncology C3 Prize® Category Winners, who will present their innovative ideas at the upcoming Union for International Cancer Control’s (UICC) 2018 World Cancer Congress (WCC) in Kuala Lumpur.
The C3 Prize, a global challenge aimed at inspiring non-treatment ideas that may improve cancer care for patients and their loved ones, is in its third year. This year, there’s a special focus on solutions for cancer care in low-and middle-income countries.
The Category Winners are…
Do Hyun Kim of Cambridge, Massachusetts, USA, Harvard University
Idea: An outpatient wearable device designed to take the body temperature readings of pediatric cancer patients at specific time intervals and inform them about the severity of their condition
Ebele Mbanugo of Lagos, Nigeria, Run For a Cure Africa Breast Cancer Foundation
Idea: Produce timely, culturally-relevant, entertaining and easy to understand information via a digital audio series about breast cancer for patients in Nigeria.
Richard Levenson of Sacramento, California, USA, UC Davis Medical Center
Idea: Update the microscope, so that it can provide diagnostic-quality images, with enhanced information, directly and quickly from fresh or fixed tissue.
Congress attendees can watch the Category Winners present their ideas to a live panel of judges for a chance to win the Grand Prize on October 3 at 15:20 MYT in Conference Hall 3. Attendees also will be able to cast their vote for their favorite pick through the WCC app.
The Category Winners are competing for a chance to win one grand prize grant of $50,000 USD, and the second and third prize winners will receive grants of $25,000 USD.
If you can’t attend this year’s event, you can hear and interact with each of the Category Winners through Astellas’ Facebook Live event on October 4. Follow us on Facebook and learn more at C3Prize.com.
Canadian Partnership Against Cancer (CPAC)
UICC Member and Partner
Sharing Canada’s 10-years of progress with the global cancer community
Evidence shows that countries with a national cancer strategy are more successful in making progress in cancer control. More than a decade ago, the Canadian cancer community came together to create one of the first such strategies. The Canadian Strategy for Cancer Control set out three ambitious 30-years goals: that fewer Canadians develop cancer, fewer die from cancer, and those affected by cancer have a better quality of life.
The Canadian Partnership Against Cancer was created in 2006 to move the Strategy into action, working with partners throughout the system to implement it and measuring its progress. To do this, we created a network model that established collaborative relationships with the provinces and territories, non-governmental organizations, researchers, health professionals and many others.
At the 2018 World Cancer Congress, we will present abstracts and participate in panels to share lessons learned, highlight accomplishments, and point to the work still to be done to achieve our 30-year goals. This includes leading two sessions with international colleagues, one focusing on how to overcome barriers to implement colorectal cancer screening in different jurisdictional settings, and one looking at why adolescents and young adults with cancer need our attention. We also hope to solicit international advice on how we can refresh our national strategy.
We look forward to learning about the advances in cancer control that will be presented at the World Cancer Congress, contributing to the momentum of shared successes and discussing innovative ways to meet the challenges ahead.
Please view the sessions that involve the Canadian Partnership Against Cancer within the main programme.
Mobilizing Oncology Carers Globally
Every day, carers around the world give their time and energy to look after loved ones with cancer. We believe that understanding the challenges these individuals face is important so that action can be taken to increase recognition of the important role they play.
As a proud sponsor of the World Cancer Congress 2018, we will be facilitating a discussion around the unmet needs of oncology carers and the unique impact of caregiving on women in our session ‘Mobilizing Oncology Carers Globally: Unique Challenges Facing Women’.
With a panel of experts, moderated by Soraya Aruajo, Merck Brazil, Government Affairs and Policy & Social Responsibility, we will take a deep-dive into existing country specific resources and best practices around supporting carers. We will also unveil new data from our Embracing Carers global survey, which looks at the unmet needs of caregivers around the world.
Please view the session that involves Merck within the main programme.